Last updated: February 10, 2022
Sponsor: John Paul II Hospital, Krakow
Overall Status: Active - Recruiting
Phase
N/A
Condition
Congestive Heart Failure
Memory Loss
Carotid Artery Disease
Treatment
N/AClinical Study ID
NCT05250349
TRACE-IMPAIR
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Clinically stable patients (NYHA I-III symptoms) with HF (for at least 6 months)either of ischemic or inflammatory etiology as well as genetic cardiomyopathies
- Signed informed consent form
- Consent to imaging studies: echocardiography, carotid and transcranial Dopplersonography and neuropsychological tests (MMSE and MoCA).
Exclusion
Exclusion Criteria:
- Co-existing, severe, irreversible disease (e.g. advanced cancer)
- Previously diagnosed dementia (including severe dementia - MMSE and MoCA score <10)
- Psychiatric condition which may influence cognitive function
- Acute, decompensated HF
- Reversible cause of HF - tachyarrhytmic, peripartum or toxic cardiomyopathy, acutemyocarditis, acute myocardial infarction
- Aortic stenosis
- Cerebral stroke in the preceding 3 months
- Lack of transcranial Doppler acoustic window
- Echocardiographic projections precluding adequate measurements
- Anemia with Hemoglobin < 8 g/dl
- Alcohol or psychoactive agents abuse
Study Design
Total Participants: 300
Study Start date:
September 01, 2021
Estimated Completion Date:
September 01, 2027
Study Description
Connect with a study center
Department of Cardiac and Vascular Diseases, The John Paul II Hospital
Kraków, MP 31-202
PolandActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.